Chemical ablation of sensory afferents in the walking system of the cat abolishes the capacity for functional recovery after peripheral nerve lesions.
Weakening the ankle extensor muscles of cats by denervation of the synergists of the medial gastrocnemius (MG) muscle results in transient increase in yield at the ankle during early stance. Recovery of ankle function occurs over a period of 1-2 weeks, is use-dependent, and is associated with increases in the strength of reflexes from MG group I muscle afferents and an increase in the magnitude of bursts in the MG muscles during stance. These observations have led to the hypothesis that feedback from large muscle afferents is necessary for functional recovery. In this investigation we have tested this hypothesis by examining functional recovery in animals treated with pyridoxine, a drug known to destroy large muscle afferents. In four adult animals we confirmed that pyridoxine abolished the group I-mediated tendon-tap reflex in the ankle extensor muscle, and subsequently found that group I afferents from MG were either destroyed or non-conducting. Immediately after pyridoxine treatment the animals showed severe locomotor dysfunction but all recovered significantly over a period of 1 or 2 months and showed only minor kinematics deficits at the time of the muscle denervations. In all four pyridoxine-treated animals, weakening of the ankle extensors by denervation of the synergists of the MG muscle resulted in a large increase in yield at the ankle that persisted almost unchanged for a month after the operation. The magnitude of burst activity in the MG muscle during early stance of the pyridoxine-treated animals either did not increase or increased only slightly after the denervation of synergists. These observations are consistent with the hypothesis that feedback from group I afferents is necessary for functional recovery in untreated animals.
Pearson
K G
KG
Department of Physiology, University of Alberta, Edmonton, T6G 2H7, Canada. keir.pearson@ualberta.ca
Misiaszek
J E
JE
Hulliger
M
M
D000344:Afferent Pathways / Q000187:drug effects / Q000293:injuries* / Q000503:physiopathology; D000818:Animals; D002415:Cats; D004576:Electromyography; D005684:Gait / Q000187:drug effects / Q000502:physiology*; D009121:Muscle Denervation / Q000009:adverse effects*; D009470:Muscle Spindles / Q000187:drug effects / Q000293:injuries* / Q000503:physiopathology; D018908:Muscle Weakness / Q000139:chemically induced / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000294:innervation / Q000502:physiology; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000502:physiology; D009473:Neuronal Plasticity / Q000502:physiology*; D009498:Neurotoxins / Q000494:pharmacology; D010523:Peripheral Nervous System Diseases / Q000503:physiopathology*; D011736:Pyridoxine / Q000494:pharmacology; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology*; D012026:Reflex, Stretch / Q000187:drug effects / Q000502:physiology
D009498:Neurotoxins; D011736:Pyridoxine